When a former “shady” hedge fund manager, who has now been called the most hated man in America, Martin Shkreli punched prices higher on a life-saving drug by over 5,000 percent, it caused an uproar in Washington D.C., drawing the ire of U.S. presidential candidate Hillary Clinton on Twitter. A prevailing thought was that the Democratic debate Tuesday night would be a forum for biotech vitriol. That didn’t happen, and biotechs are rallying on the no news is good news mantra. I am pretty sure @MartinShkreli is pissed he didnt get a #DemocraticDebate shoutout — Dan Rosenblum (@sharkbiotech) October 14, 2015…
Biotech Index Jumps As No News From Democratic Debate Is Good News
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.